FDA expands approval of BioCryst's rare disease drug for use in young childrenDec 12 (Reuters) - The U.S. Food and Drug Administration has expanded the use of BioCryst Pharmaceuticals' BCRX.O drug to include an oral pellet formulation for preventing hereditary angioedema attacks in children aged 2 to under 12 years, the company said on Friday.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Shailesh Kuber)
((siddhi.mahatole@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments